NEW YORK, July 1 (Reuters) - Shares of Sepracor Inc SEPR.O fell 16.2 percent after the closing bell on Wednesday after news the company's experimental depression drug failed a mid-stage study and U.S. regulators halted two pediatric studies of its Lunesta insomnia pill.
Shares were down at $15 after closing on Nasdaq at $17.89.
© Thomson Reuters 2009 All rights reserved.
UK
USuk.reuters.com
Help and Contact Us |
Advertise With Us |
Mobile |
Newsletters |
RSS
|
Interactive TV |
Labs |
Archive |
Site Index |
Video Index
Thomson Reuters Corporate: Copyright | Disclaimer | Privacy | Professional Products | Professional Products Support | About Thomson Reuters | Careers
International Editions: Africa | Arabic | Argentina | Brazil | Canada | China | France | Germany | India | Italy | Japan | Latin America | Mexico | Russia | Spain | United Kingdom | United States
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Dubai debt problems shock